Optimizing the management of thrombosis in the antiphospholipid-antibody syndrome.
نویسندگان
چکیده
BACKGROUND The antiphospholipid-antibody syndrome is a thrombophilic disorder in which venous or arterial thrombosis, or both, may occur in patients with antiphospholipid antibodies. The optimal treatment of these patients is unclear. We assessed the efficacy of warfarin, low-dose aspirin, or both in the secondary prevention of thrombosis in patients with the syndrome. METHODS One hundred forty-seven patients (124 [84 percent] of whom were female) with the antiphospholipid-antibody syndrome and a history of thrombosis were studied retrospectively. The syndrome was primary in 62 patients and was associated with systemic lupus erythematosus in 66 patients and lupus-like disease in 19. Each patient's history was reviewed. RESULTS One hundred one patients (69 percent) had a total of 186 recurrences of thrombosis. The median time between the initial thrombosis and the first recurrence was 12 months (range, 0.5 to 144 months). Treatment with high-intensity warfarin (producing an international normalized ratio of > or = 3) with or without low-dose aspirin (75 mg per day) was significantly more effective (P < 0.001 by the log-rank test) than treatment with low-intensity warfarin (producing an international normalized ratio of < 3) with or without low-dose aspirin or treatment with aspirin alone in preventing further thrombotic events (recurrence rates per patient-year, 0.013, 0.23, and 0.18, respectively). The rate of recurrence of thrombosis was highest (1.30 per patient-year) during the first six months after the cessation of warfarin therapy. Complications involving bleeding occurred in 29 patients during warfarin therapy and were severe in 7 (0.071 and 0.017 occurrence per patient-year, respectively). CONCLUSIONS The risk of recurrent thrombosis in patients with the antiphospholipid-antibody syndrome is high. Long-term anticoagulation therapy in which the international normalized ratio is maintained at or above 3 is advisable in these patients.
منابع مشابه
New clinical and laboratory finding in anti-phospholipid syndromes
Antiphospholipid syndrome (APS) is a systemic autoimmune disease with the appearance of anti-phospholipid antibody (ACLA), Anti β2GPI and lupus anticoagulant (LAC) in serum. The antigen-antibody reaction on cell surface leads to thrombosis, miscarriage and inflammation. Clinical findings are diverse and include thrombosis in veins and arteries, pregnancy loss, thrombocytopenia, neurological and...
متن کاملComparison of Antiphospholipid Antibodies between Preeclamptsia and Normal Pregnant Women
Antiphospholipid antibodies (APLA) may be detected in normal pregnancies and also may cause thrombosis, recurrent fetal loss, placental infarction and preeclampsia. In the present study the possible differences in APLA titer between healthy pregnant women and preeclampsia cases without history of thrombosis was examined. The APLA titer in 50 healthy pregnant women with 50 preeclampsia cases wit...
متن کاملOral contraceptive-related transverse sinus thrombosis as an initial manifestation of antiphospholipid syndrome in the absence of systemic lupus erythematosus
متن کامل
معرفی و بررسی یک مورد بیمار مبتلا به سندرم آنتی فسفولیپید آنتی بادی در زمینه لوپوس سیستمیک، با تظاهر اولیه کره
Manifestation of chorea in patients with systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APA synd.) is not common. Moreover, primary presentation of the disease with chorea is rare and only few such cases are reported in literature in recent years. We report here the case of a 28 year old woman who was first seen at the age of 10 with clinical manifestations of chorea...
متن کاملP-75: The Association of Antiphospholipid Syndrome and Recurrent Miscarriages
a:4:{s:10:"Background";s:364:"Antiphospholipid syndrome is a coagulation disorder that causes recurrent miscarriages and fetal deaths. In the present review we summarize current knowledge about Antiphospholipid syndrome that associated with recurrent miscarriages. In addition, on the basis of these comprehensive data, possible pathophysiologic mechanisms of this disorder are discussed.";s:19:"M...
متن کاملAnticardiolipin Antibodies in Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background: Antiphospholipid antibody syndrome (APS) can either occur as a primary syndrome or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in blood, measured by a standardized ELISA is the most acceptable laboratory criteria. APS IgG isotype, particularly IgG2 subclass is more strongly associated ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The New England journal of medicine
دوره 332 15 شماره
صفحات -
تاریخ انتشار 1995